NEW YORK – A pediatric cancer study assessing the feasibility of precision oncology for pediatric patients in a real-world setting found that about 28 percent of refractory, relapsed, and progressive high-risk pediatric cancer patients with poor prognosis were able to be treated with targeted therapies.